enGene to Participate in the Leerink Partners Global Healthcare Conference

enGene to Participate in the Leerink Partners Global Healthcare Conference

BOSTON & MONTREAL–(BUSINESS WIRE)–
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, taking place in Miami, FL on Tuesday, March 11, 2025, at 1:00 p.m. ET.

A live webcast of the fireside chat can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days.

About enGene

enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

To learn more, please visitenGene.com and follow us on LinkedIn, X and BlueSky.

For media contact:

908-577-4531

[email protected]

For investor contact:

[email protected]

KEYWORDS: Florida Massachusetts United States North America Canada

INDUSTRY KEYWORDS: Health Genetics Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

Company will temporarily pause CONNECT2 and focus efforts on ongoing CONNECT1-EDO51 study of PGN-EDO51 in DMD, with 10 mg/kg results expected in the third quarter of 2025

No new safety issues have been observed in PGN-EDO51 program

BOSTON–(BUSINESS WIRE)–
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the Company can review results from the 10 mg/kg cohort in the ongoing Phase 2 CONNECT1-EDO51 study. The first two cohorts of the CONNECT1 study are fully enrolled and data from the 10 mg/kg cohort are expected during the third quarter of 2025. No new safety issues related to PGN-EDO51 have been observed since the Company’s last safety update as of January 23, 2025.

“With our 10 mg/kg cohort of CONNECT1 study fully enrolled and data expected later this year, we decided to pause CONNECT2 until we are able to review results from the 10 mg/kg cohort in patients with DMD. This will allow us to gather additional safety data, assess the impact of this dose of PGN-EDO51 on dystrophin levels, and potentially improve the design of CONNECT2,” said James McArthur, PhD, President and CEO of PepGen. “This decision enables us to focus resources on completing CONNECT1, as well as rapidly advancing our FREEDOM studies in myotonic dystrophy type 1 with PGN-EDODM1, in which we recently reported encouraging initial clinical data from the Phase 1 FREEDOM-DM1 study.”

About PGN-EDO51

PGN-EDO51, PepGen’s investigational candidate in development for the treatment of DMD, utilizes the Company’s proprietary Enhanced Delivery Oligonucleotide (EDO) technology to deliver a therapeutic oligonucleotide that is designed to target the root cause of this devastating disease. PGN-EDO51 is designed to skip exon 51 of the dystrophin transcript, an established therapeutic target for approximately 13% of DMD patients, thereby aiming to restore the open reading frame and enabling the production of a truncated, yet functional dystrophin protein. The U.S. Food and Drug Administration (FDA) has granted PGN-EDO51 both Orphan Drug and Rare Pediatric Disease Designations for the treatment of patients with DMD amenable to an exon 51-skipping approach.

About the CONNECT Clinical Program

CONNECT1-EDO51 is an open-label, multiple ascending dose Phase 2 trial being conducted in Canada. CONNECT1 has enrolled two cohorts of boys and young men living with DMD amenable to exon 51 skipping and its endpoints include safety and tolerability, dystrophin production, exon skipping, and muscle tissue concentration. The 10 mg/kg cohort is fully enrolled (n=4) and participants in the 5 mg/kg cohort (n=3) are continuing to dose at that level in the long-term extension phase of the study. The Company has received communication from Health Canada that dosing of patients in the 5 and 10 mg/kg cohorts may continue at their current dose levels and has requested additional information from the Company to address Health Canada’s safety concerns before any further dose escalation or enrollment of any additional participants at the current dose levels. The Company is working with Health Canada to address its questions.

CONNECT2-EDO51 is a double-blind, placebo-controlled, multiple ascending dose Phase 2 trial designed to evaluate PGN-EDO51 at dose levels administered intravenously once every four weeks for 24 weeks in patients with DMD amenable to an exon 51-skipping approach. Endpoints include safety and tolerability, dystrophin production, exon skipping, and functional outcome measures. In December, the Company announced that it had received a clinical hold notice from the FDA regarding its Investigational New Drug application to initiate the CONNECT2 clinical trial in the U.S. The Company is working with the FDA to address its questions regarding supportive data for the dosing levels planned for the patient population.

About PepGen

PepGen is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s EDO platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.

For more information, please visit PepGen.com. Follow PepGen on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the voluntary pause of the CONNECT2-EDO51 study to enable review of additional results from the CONNECT1-EDO51 study expected in the third quarter of 2025, the advancement of our FREEDOM studies, the therapeutic potential and safety profile of our product candidates, PGN-EDO51 and PGN-EDODM1, including based on early clinical data, the expected timing for an additional data report from our CONNECT1 Phase 2 trial, and ongoing and planned regulatory interactions.

Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: delays or failure to successfully initiate or complete our ongoing and planned development activities for our product candidates, including PGN-EDO51 and PGN-EDODM1; our ability to enroll patients in our clinical trials, including FREEDOM and FREEDOM2; that our interpretation of clinical and preclinical study results may be incorrect, or that we may not observe the levels of therapeutic activity in clinical testing that we anticipate based on prior clinical or preclinical results, including for PGN-EDO51 and PGN-EDODM1; our product candidates, including PGN-EDO51 and PGN-EDODM1, may not be safe and effective or otherwise demonstrate safety and efficacy in our clinical trials; adverse outcomes from our regulatory interactions, including delays in regulatory review, clearance to proceed or approval by regulatory authorities with respect to our programs, including clearance to commence planned clinical studies of our product candidates, or other regulatory feedback requiring modifications to our development programs, including in each case with respect to our CONNECT1, CONNECT2, FREEDOM and FREEDOM2 clinical trials; changes in regulatory framework that are out of our control; unexpected increases in the expenses associated with our development activities or other events that adversely impact our financial resources and cash runway; and our dependence on third parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning PepGen’s programs and operations are described in our most recent annual report on Form 10-Kthat is filed with the SEC. PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

This release discusses PGN-EDO51 and PGN-EDODM1, investigational therapies that have not been approved for use in any country and is not intended to convey conclusions about their efficacy or safety. There is no guarantee that PGN-EDO51, PGN-EDODM1 or any other investigational therapy will successfully complete clinical development or gain regulatory authority approval.

Investor Contact

Dave Borah, CFA

SVP, Investor Relations and Corporate Communications

[email protected]

Media Contact

Julia Deutsch

Lyra Strategic Advisory

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health Neurology Clinical Trials Research Science Biotechnology

MEDIA:

Logo
Logo

The Marygold Companies’ Original Sprout Subsidiary Expands Marketing Reach With Product Exhibit at Global Trade Show

The Marygold Companies’ Original Sprout Subsidiary Expands Marketing Reach With Product Exhibit at Global Trade Show

-Company to Introduce Tahitian Collection at Natural Products Expo West 2025-

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–
The Marygold Companies, Inc. (“TMC” or the “Company”), (NYSE American: MGLD), a diversified global holding company, today announced that its wholly owned subsidiary, Original Sprout, will introduce its Tahitian Collection at the Natural Products Expo West 2025 trade show, March 5-7, at the Anaheim Convention Center, in Anaheim, Calif.

Expo West is considered the leading trade show in the natural, organic and healthy lifestyle industry, with more than 65,000 expected attendees, providing an opportunity for Original Sprout to showcase its products to buyers from leading retailers, product distributors, healthcare practitioners and other industry professionals from throughout the world.

Original Sprout gained notoriety more than 20 years ago through introduction of its 100% vegan, non-toxic, safe and effective hair and body washes that initially were formulated for babies. Since then, through its Tahitian Collection, Original Sprout significantly expanded its product line to more than 25 SKUs, offering a full range of hair and skin care products for the entire family.

“Our babies have grown up!” said Michael Ambacher, CEO of Original Sprout. “We have devoted the past few years to formulating an effective line of products intended for adults that are based on our proprietary 100% vegan, non-toxic, lab-tested blends of natural extracts originally used in our baby products. We also have taken another step forward, packaging our products in recycled and recyclable containers, doing our part to help keep the planet clean.”

Eric Glover, Original Sprout’s Marketing Director, said, “We are thrilled to introduce our enhanced Tahitian Collection line at Expo West this year. Original Sprout continues its tradition of creating family-friendly personal care products that are free from harmful chemicals, parabens, sulfates and phthalates. The Tahitian Collection embodies the brand’s philosophy of combining nature’s finest ingredients with cutting-edge formulation science. Expo West is the perfect venue to introduce the Tahitian Collection and reach thousands of our industry’s most influential representatives.”

David Neibert, TMC’s Chief Operations Officer, added, “Original Sprout is an important component in our portfolio of operating companies. Through product innovation, increased distribution and positive brand exposure at events such as Expo West, we expect that Original Sprout will continue to grow and be a solid contributor to our corporate performance.”

About Original Sprout

Founded in 2003 by a professional hair stylist with a newborn baby, Original Sprout gained recognition as a leader in non-toxic, safe, effective baby wash products. The product line has grown to include a full complement of hair and skin care solutions for all family members. Original Sprout, operating from facilities in San Clemente, Calif. and distributed throughout the world, was acquired by The Marygold Companies in 2017. For more information visit www.originalsprout.com.

Follow Original Sprout on Instagram, Facebook, TikTok, Pinterest, and LinkedIn.

About The Marygold Companies, Inc.

The Marygold Companies was founded in 1996 and repositioned as a global holding firm in 2015. The Company currently has operating subsidiaries in financial services, food manufacturing, printing, security systems and beauty products, under the trade names USCF Investments, Marygold & Co., Marygold & Co Limited, Step By Step Financial Planners, Gourmet Foods, Printstock Products, Brigadier Security Systems and Original Sprout, respectively. Offices and manufacturing operations are in the U.S., New Zealand, U.K., and Canada. For more information, visit www.themarygoldcompanies.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of U.S. federal securities laws. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may” “will,” “could,” “should” “believes,” “predicts,” “potential,” “continue” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. Readers should refer to the further detail of the risks disclosed in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission and in the Company’s other filings with the Securities and Exchange Commission. The foregoing list of factors is not exclusive. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Except as required by law, the Company disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release.

Media and investors, for more Information, contact:

Roger S. Pondel

PondelWilkinson Inc.

310-279-5965

[email protected]

Contact the Company:

David Neibert, Chief Operations Officer

949-429-5370

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Women Men Family Baby/Maternity Lifestyle Consumer Cosmetics Retail

MEDIA:

KB Home Announces the Grand Opening of Two New Communities in a Prime South El Monte, California Location

KB Home Announces the Grand Opening of Two New Communities in a Prime South El Monte, California Location

Astaire and Harlow at Starlite offer personalized, new homes with planned on-site resort-style amenities and close to local schools, priced from the $720,000s.

SOUTH EL MONTE, Calif.–(BUSINESS WIRE)–
KB Home (NYSE: KBH), one of the largest and most trusted homebuilders in the U.S., today announced the grand opening of Astaire and Harlow at Starlite, two new communities in a prime South El Monte, California location. The new homes are designed for the way people live today, with popular features like modern kitchens overlooking large great rooms, bedroom suites with walk-in closets and ample storage. The three-story, single-family homes at Astaire and three-story townhomes at Harlow offer up to four bedrooms and three-and-a-half baths. Homeowners will appreciate the communities’ proximity to local schools as well as the planned resort-style amenities, which include a recreation center, pool, spa, open space and walking paths. Additionally, the communities are located at the site of the old Starlite drive-in movie theater, a neighborhood landmark whose historic marquee will be restored to its former glory and serve as a beautiful entrance monument.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250304103027/en/

KB Home announces the grand opening of Astaire at Starlite, a new community in a prime South El Monte, California location. (Photo: Business Wire)

KB Home announces the grand opening of Astaire at Starlite, a new community in a prime South El Monte, California location. (Photo: Business Wire)

What sets KB Home apart is the company’s focus on building strong, personal relationships with every customer, so they have a real partner in the homebuying process. Every KB home is uniquely built for each customer, so no two KB homes are the same. Homebuyers have the ability to personalize their new home, from floor plans to where they live in the community. Their home comes to life in the KB Home Design Studio, a one-of-a-kind experience where customers get both expert advice and the opportunity to select from a wide range of design choices that fit their style and their budget. Reflecting the company’s commitment to creating an exceptional homebuying experience, KB Home is the #1 customer-ranked national homebuilder based on homebuyer satisfaction surveys from a leading third-party review site.

“We are pleased to offer Southern California homebuyers spacious new single-family homes and townhomes in a prime South El Monte location,” said Keltie Cole, President of KB Home’s Los Angeles and Ventura Counties division. “Astaire and Harlow are close to local schools and feature planned on-site resort-style amenities, including a recreation center, pool, spa, open space and walking paths. At KB Home, we’re here to help you achieve your dream with a personalized new home built uniquely for you and your life.”

Innovative design plays an essential role in every home KB builds. The company’s floor plans inspire contemporary living, with a focus on roomy, light-filled spaces that have easy indoor/outdoor flow. KB homes are engineered to be highly energy and water efficient and include features that support healthier indoor environments. They are also designed to be ENERGY STAR® certified — a standard that fewer than 12% of new homes nationwide meet — offering greater comfort, well-being and utility cost savings than new homes without certification.

Astaire and Harlow at Starlite are situated in a commuter-friendly location that offers homebuyers an exceptional lifestyle. The new communities are located on Rosemead Boulevard at the site of the old Starlite drive-in movie theater, close to Interstate 10, Interstate 605 and Highway 60, providing easy access to downtown Los Angeles, the area’s major employment centers and Los Angeles International Airport. Starlite is convenient to popular shopping, dining and entertainment in South El Monte and near outdoor recreation, including golfing at Whittier Narrows Golf Course and hiking and biking at Sycamore Canyon and Hacienda Hills Trailheads.

The Astaire and Harlow at Starlite sales office and model homes are open for walk-in visits and private in-person tours by appointment. Homebuyers also have the flexibility to arrange a live video tour with a sales counselor. Pricing begins from the $720,000s.

For more information on KB Home, call 888-KB-HOMES or visit kbhome.com.

About KB Home

KB Home is one of the largest and most trusted homebuilders in the United States. We operate in 47 markets, have built over 680,000 quality homes in our more than 65-year history, and are honored to be the #1 customer-ranked national homebuilder based on third-party buyer surveys. What sets KB Home apart is building strong, personal relationships with every customer and creating an exceptional experience that offers our homebuyers the ability to personalize their home based on what they value at a price they can afford. As the industry leader in sustainability, KB Home has achieved one of the highest residential energy-efficiency ratings and delivered more ENERGY STAR® certified homes than any other builder, helping to lower the total cost of homeownership. For more information, visit kbhome.com.

Craig LeMessurier, KB Home

925-580-1583

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Architecture Construction & Property Sustainability Environment Urban Planning Landscape Interior Design Residential Building & Real Estate

MEDIA:

Photo
Photo
KB Home announces the grand opening of Astaire at Starlite, a new community in a prime South El Monte, California location. (Photo: Business Wire)
Photo
Photo
KB Home announces the grand opening of Harlow at Starlite, a new community in a prime South El Monte, California location. (Photo: Business Wire)
Logo
Logo

1-800Accountant Adopts Salesforce’s Agentforce to Scale Expertise During Tax Season Surge, Now Resolving 50% of Customer Support Inquiries with Digital Labor

1-800Accountant Adopts Salesforce’s Agentforce to Scale Expertise During Tax Season Surge, Now Resolving 50% of Customer Support Inquiries with Digital Labor

1-800Accountant leverages Agentforce to ease surges in customer support inquiries

In the first 24 hours alone, Agentforce resolved over 1,000 client engagements

SAN FRANCISCO & NEW YORK–(BUSINESS WIRE)–
Salesforce (NYSE: CRM), the world’s #1 AI CRM, today announced that 1-800Accountant, America’s largest virtual accounting firm for small businesses and entrepreneurs, is using Agentforce to enhance its customer service support.

American taxpayers estimate that approximately 62% of their time is wasted responding to confusing or redundant questions while filing taxes, according to a Salesforce survey1. With a projected 40% increase in client growth in 2025 and anticipated surges in tax season, 1-800Accountant recognized the need to deliver consistently fast, accurate, and personalized support no matter how much it grew or how tax laws changed.

Agentforce — the digital labor solution for enterprises — now supports 1-800Accountant service teams and customers with streamlined, 24/7 support. For example, Agentforce can provide immediate answers to complicated tax questions such as, “What charitable donations can I deduct?”

“Agentforce is a game-changer, helping us scale and serve our clients better during peak times,” said Ryan Teeples, Chief Technology Officer, 1-800Accountant. “With Agentforce now helping to resolve up to 50% of incoming requests, we can securely address responses to questions like tax return status, freeing our team to focus on more complex tasks while ensuring fast, secure, personalized support.”

Agentforce reasons across client data — including audit logs and support history — from Sales Cloud, Service Cloud, and more all harmonized in Data Cloud, as well as trusted public sources like the IRS website. This combination powers quick, personalized answers — no hold times or phone calls needed. By integrating everything needed to design, develop, and deploy trusted agents, the deeply unified Salesforce Platform seamlessly integrates Customer 360 apps, Data Cloud, and Agentforce.

“1-800Accountant provides financial and accounting expertise to small businesses across the country, and delivering high quality customer support at scale is fundamental to their business,” said Adam Evans, EVP and GM, Salesforce AI. “With Agentforce, they’re able to implement new agentic AI solutions to make meaningful improvements to customer satisfaction while also improving the work experience for their dedicated customer representatives. They’re able to do this quickly and easily by taking advantage of the work they’ve already done with Salesforce’s deeply unified platform, which helps everything work in harmony.”

More information:

* Any unreleased services or features referenced in this post are not currently available and may not be delivered on time or at all. Customers who purchase Salesforce applications should make their purchase decisions based upon features that are currently available.

About Salesforce

Salesforce helps organizations of any size reimagine their business with AI. Agentforce — the first digital labor solution for enterprises — seamlessly integrates with Customer 360 applications, Data Cloud, and Einstein AI to create a limitless workforce, bringing humans and agents together to deliver customer success on a single, trusted platform. Visit www.salesforce.com for more information.

About 1-800Accountant

1-800Accountant offers services for new and experienced small business owners, with advisory support from expert CPAs and accounting professionals. Services are efficient, affordable, and can be used individually or bundled together for maximum impact, empowering owners to focus on growth throughout their business journey. Learn more at https://1800accountant.com/about.

_____________________________

1Data from the Agentic AI Snapshot Series: Public Sector study are from a double-anonymous survey conducted from November 27 to December 17, 2024. The survey generated 11,500 responses from adults across North America, Latin America, Asia-Pacific, and Europe; 1,000 of these respondents were based in the United States.

Emily Cleffi-Tristani

[email protected]

KEYWORDS: United States North America California New York

INDUSTRY KEYWORDS: Data Management Entrepreneur Accounting Technology Professional Services Small Business Apps/Applications Data Analytics Software Artificial Intelligence Consumer

MEDIA:

QXO Reports Fourth Quarter 2024 Results

QXO Reports Fourth Quarter 2024 Results

GREENWICH, Conn.–(BUSINESS WIRE)–
QXO, Inc. (NYSE: QXO) today announced its financial results for the fourth quarter 2024. The company reported a loss of $(0.02) per basic and diluted shares attributable to common shareholders.

For the full year 2024, the company reported a loss of $(0.11) per basic and diluted shares attributable to common shareholders.

FOURTH QUARTER AND FULL YEAR 2024 SUMMARY RESULTS

   
   

Three Months Ended

December 31,

 Year Ended

December 31,

 

(in thousands)

2024

 

2023

Change %

2024

 

2023

Change %

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Software product, net

$

4,977

 

$

4,640

7.3

%

$

15,261

 

$

14,111

 

8.1

%

Service and other, net

 

9,766

 

 

10,069

(3.0

)%

 

41,612

 

 

40,406

 

3.0

%

Total revenue, net

$

14,743

 

$

14,709

0.2

%

$

56,873

 

$

54,517

 

4.3

%

 

 

 

 

 

 

 

Net income (loss)

$

11,289

 

$

419

NM

 

$

27,969

 

$

(1,070

)

NM

 

 

 

 

 

 

 

 

Adjusted EBITDA¹

NM – Not Meaningful

$

(7,655

)

$

684

NM

 

$

(19,832

)

$

2,717

 

NM

 

¹ See “Non-GAAP Financial Measures” section for additional information.

 

“We are making significant strides in establishing QXO as a tech-forward leader in the $800 billion building products distribution industry,” said Brad Jacobs, chairman and chief executive officer of QXO. “Our strong balance sheet, including more than $5 billion of cash and no debt, is enabling our world-class leadership team to pursue high-value M&A opportunities.”

Fourth Quarter Highlights

Total revenue for the quarter was $14.7 million, compared with $14.7 million for the same period in 2023. Software product revenue was $5.0 million, compared with $4.6 million for the same period in 2023. Service and other revenue was $9.8 million, compared with $10.1 million for the same period in 2023.

Net income, inclusive of $61.4 million interest income, was $11.3 million.

Adjusted EBITDA, a non-GAAP measure, was a loss of $(7.7) million, compared with a gain of $0.7 million for the same period in 2023. The year-over-year decrease in adjusted EBITDA reflects costs related to the introduction of a new senior management team to execute QXO’s expansive growth plan.

As of December 31, 2024, the company had approximately $5.1 billion in cash on hand and no debt.

About QXO

QXO provides technology solutions, primarily to clients in the manufacturing, distribution and service sectors. The company provides consulting and professional services, including specialized programming, training and technical support, and develops proprietary software. As a value-added reseller of business application software, QXO offers solutions for accounting, financial reporting, enterprise resource planning, warehouse management systems, customer relationship management, business intelligence and other applications. QXO plans to become a tech-forward leader in the $800 billion building products distribution industry. The company is targeting tens of billions of dollars of annual revenue in the next decade through accretive acquisitions and organic growth. Visit QXO.com for more information.

Non-GAAP Financial Measures

As required by the rules of the SEC, we provide reconciliations of the non-GAAP financial measures contained in this press release to the most directly comparable measure under GAAP, which are set forth in the financial tables attached to this press release. QXO’s non-GAAP financial measure in this press release is adjusted EBITDA.

We believe that the above adjusted financial measure facilitates analysis of our ongoing business operations because it excludes items that may not be reflective of, or are unrelated to, QXO’s core operating performance, and may assist investors with comparisons to prior periods and assessing trends in our underlying business. Other companies may calculate this non-GAAP financial measure differently, and therefore our measure may not be comparable to similarly titled measures of other companies. This non-GAAP financial measure should only be used as a supplemental measure of our operating performance.

Adjusted EBITDA includes adjustments for share-based compensation, transaction, and severance costs as set forth in the attached reconciliation. Transaction adjustments are generally incremental costs that result from an actual or planned acquisition or divestiture and may include transaction costs, consulting fees, retention awards, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems. Management uses this non-GAAP financial measure in making financial, operating and planning decisions and evaluating QXO’s ongoing performance.

We believe that adjusted EBITDA improves comparability from period to period by removing the impact of our capital structure (interest and financing expenses), asset base (depreciation and amortization), tax impacts and other adjustments as set out in the attached tables that management has determined are not reflective of core operating activities and thereby assist investors with assessing trends in our underlying businesses.

Because of these limitations, you should consider adjusted EBITDA alongside other financial performance measures, including various cash flow metrics, net income (loss), and our other GAAP results.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical facts, including statements about beliefs, expectations, targets and goals are forward-looking statements. These statements are based on plans, estimates, expectations and/or goals at the time the statements are made, and readers should not place undue reliance on them. In some cases, readers can identify forward-looking statements by the use of forward-looking terms such as “may,” “will,” “should,” “expect,” “opportunity,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “target,” “goal,” or “continue,” or the negative of these terms or other comparable terms. Forward-looking statements involve inherent risks and uncertainties and readers are cautioned that a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statements. Factors that could cause actual results to differ materially from those described herein include, among others:

  • risks associated with potential significant volatility and fluctuations in the market price of the company’s common stock;

  • risks associated with raising additional equity or debt capital from public or private markets to pursue the company’s business plan, including potentially one or more additional private placements of common stock, and the effects that raising such capital may have on the company and its business, including the risk of substantial dilution or that the company’s common stock may experience a substantial decline in trading price;

  • the possibility that additional future financings may not be available to the company on acceptable terms or at all;

  • the possibility that an active, liquid trading market for the company’s common stock may not be sustained;

  • the possibility that the company’s outstanding warrants and preferred stock may or may not be converted or exercised, and the economic impact on the company and the holders of common stock of the company that may result from either such exercise or conversion, including dilution, or the continuance of the preferred stock remaining outstanding, and the impact its terms, including its dividend, may have on the company and the common stock of the company;

  • uncertainties regarding the company’s focus, strategic plans and other management actions;

  • the risk that the company is or becomes highly dependent on the continued leadership of Brad Jacobs as chairman and chief executive officer and the possibility that the loss of Mr. Jacobs in these roles could have a material adverse effect on the company’s business, financial condition and results of operations;

  • the possibility that the concentration of ownership by Mr. Jacobs may have the effect of delaying or preventing a change in control of the company and might affect the market price of shares of the common stock of the company;

  • the risk that Mr. Jacobs’ past performance may not be representative of future results;

  • the risk that the company is unable to attract and retain world-class talent;

  • the risk that the failure to consummate any acquisition expeditiously, or at all, could have a material adverse effect on the company’s business prospects, financial condition, results of operations or the price of the company’s common stock;

  • risks that the company may not be able to enter into agreements with acquisition targets on attractive terms, or at all, that agreed acquisitions may not be consummated, or, if consummated, that the anticipated benefits thereof may not be realized and that the company encounter difficulties in integrating and operating such acquired companies, or that matters related to an acquired business (including operating results or liabilities or contingencies) may have a negative effect on the company or its securities or ability to implement its business strategy, including that any such transaction may be dilutive or have other negative consequences to the company and its value or the trading prices of its securities;

  • risks associated with cybersecurity and technology, including attempts by third parties to defeat the security measures of the company and its business partners, and the loss of confidential information and other business disruptions;

  • the possibility that new investors in any future financing transactions could gain rights, preferences and privileges senior to those of the company’s existing stockholders;

  • the possibility that building products distribution industry demand may soften or shift substantially due to cyclicality or seasonality or dependence on general economic and political conditions, including inflation or deflation, interest rates, governmental subsidies or incentives, consumer confidence, labor and supply shortages, weather and commodity prices;

  • the possibility that regional or global barriers to trade or a global trade war could increase the cost of products in the building products distribution industry, which could adversely impact the competitiveness of such products and the financial results of businesses in the industry;

  • risks associated with periodic litigation, regulatory proceedings and enforcement actions, which may adversely affect the company’s business and financial performance;

  • uncertainties regarding general economic, business, competitive, legal, regulatory, tax and geopolitical conditions; and

  • other factors, including those set forth in the company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

The company cautions that forward-looking statements should not be relied on as predictions of future events, and these statements are not guarantees of performance or results. Forward-looking statements herein speak only as of the date each statement is made. The company undertakes no obligation to update any of these statements in light of new information or future events, except to the extent required by applicable law.

 

 QXO, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 
 

December 31,

2024

December 31,

2023

ASSETS

 

Current assets:

 

 

Cash and cash equivalents

$

5,068,504

 

$

6,143

 

Accounts receivable, net

 

2,736

 

 

2,969

 

Prepaid expenses and other current assets

 

18,339

 

 

2,684

 

Total current assets

 

5,089,579

 

 

11,796

 

Property and equipment, net

 

445

 

 

503

 

Operating lease right-of-use assets

 

259

 

 

522

 

Intangible assets, net

 

4,024

 

 

4,919

 

Goodwill

 

1,160

 

 

1,140

 

Deferred tax assets

 

2,603

 

 

1,444

 

Other non-current assets

 

192

 

 

171

 

Total assets

$

5,098,262

 

$

20,495

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

 

 

Accounts payable

$

6,194

 

$

4,563

 

Accrued expenses

 

35,692

 

 

2,681

 

Deferred revenue

 

2,900

 

 

3,161

 

Long-term debt – current portion

 

 

 

702

 

Finance lease obligations – current portion

 

128

 

 

154

 

Operating lease liabilities – current portion

 

188

 

 

263

 

Total current liabilities

 

45,102

 

 

11,524

 

Long-term debt net of current portion

 

 

 

994

 

Finance lease obligations net of current portion

 

190

 

 

247

 

Operating lease liabilities net of current portion

 

71

 

 

259

 

Total liabilities

 

45,363

 

 

13,024

 

Stockholders’ equity:

 

 

Preferred stock, $0.001 par value; authorized 10,000,000 shares, 1,000,000 and 0 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively

 

498,621

 

 

 

Common stock, $0.00001 par value; authorized 2,000,000,000 shares, 409,430,195 and 664,448 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively

 

 

 

4

 

 

 

 

 

 

 

Additional paid-in capital

 

4,560,503

 

 

9,419

 

Accumulated deficit

 

(6,229

)

 

(1,948

)

Total stockholders’ equity

 

5,052,899

 

 

7,471

 

Total liabilities and stockholders’ equity

$

5,098,262

$

20,495

 

 QXO, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

 
 

Three Months Ended December 31,

Year Ended December 31,

2024

2023

2024

2023

Revenue:

(Unaudited)

 

Software product, net

$

4,977

 

$

4,640

 

$

15,261

 

$

14,111

 

Service and other, net

 

9,766

 

 

10,069

 

 

41,612

 

 

40,406

 

Total revenue, net

 

14,743

 

 

14,709

 

 

56,873

 

 

54,517

 

Cost of revenue:

 

 

 

 

Software product

 

3,044

 

 

2,799

 

 

9,434

 

 

8,513

 

Service and other

 

5,661

 

 

6,189

 

 

24,507

 

 

24,390

 

Total cost of revenue

 

8,705

 

 

8,988

 

 

33,941

 

 

32,903

 

Operating expenses:

 

 

 

 

Selling, general and administrative expenses

 

38,896

 

 

 

5,079

 

 

92,943

 

 

22,097

 

Depreciation and amortization expenses

 

243

 

 

 

220

 

 

989

 

 

828

 

Total operating expenses

 

39,139

 

 

 

5,299

 

 

93,932

 

 

22,925

 

(Loss) income from operations

 

(33,101

)

 

 

422

 

 

(71,000

)

 

(1,311

)

Other income (expense), net:

 

 

 

 

 

Interest income (expense), net

 

61,374

 

 

 

(14

)

 

121,812

 

 

(56

)

Total other income (expense)

 

61,374

 

 

 

(14

)

 

121,812

 

 

(56

)

Income (loss) before taxes

 

28,273

 

 

 

408

 

 

50,812

 

 

(1,367

)

Provision (benefit) for income taxes

 

16,984

 

 

 

(11

)

 

22,843

 

 

(297

)

Net income (loss)

$

11,289

 

$

 

419

 

$

27,969

 

$

(1,070

)

(Loss) earnings per common share – basic and diluted

$

(0.02

)

$

0.64

 

$

(0.11

)

$

(1.63

)

Total weighted average common shares outstanding:

 

 

 

 

Basic

 

451,430

 

 

659

 

 

203,998

 

 

657

 

Diluted

451,430

659

203,998

657

 
 

 QXO, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 
 

Year Ended

December 31,

 

2024

2023

Cash flows from operating activities:

 

 

Net income (loss)

$

27,969

 

$

(1,070

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

Deferred income taxes

 

(1,159

)

 

(338

)

Depreciation

 

247

 

 

329

 

Amortization of intangibles

 

875

 

 

672

 

Non-cash lease expense

 

263

 

 

126

 

Provision for expected losses

 

50

 

 

115

 

Share-based compensation

 

34,513

 

 

41

 

Changes in assets and liabilities:

 

 

Accounts receivable

 

183

 

 

103

 

Prepaid expenses and other current assets

 

(12,155

)

 

(179

)

Other assets

 

(21

)

 

16

 

Accounts payable

 

1,631

 

 

1,291

 

Accrued expenses

 

33,011

 

 

222

 

Deferred revenue

 

(261

)

 

(618

)

Operating lease liabilities

 

(263

)

 

(126

)

Net cash provided by operating activities

 

84,883

 

 

584

 

Cash flows from investing activities:

 

 

Purchase of property and equipment

 

(102

)

 

(121

)

Acquisition of assets

 

 

 

(279

)

Net cash used in investing activities

 

(102

)

 

(400

)

Cash flows from financing activities:

 

 

Proceeds from the issuance of common stock and pre-funded warrants, net of issuance costs

4,051,103

 

Proceeds from issuance of preferred stock and warrants, net of issuance costs

 

981,538

 

 

 

Payment of preferred stock dividend

 

(32,250

)

 

 

Payment of common-stock dividend

 

(17,400

)

 

(1,051

)

Payment of long-term debt

 

(1,696

)

 

(784

)

Payment for fractional shares

 

(45

)

 

 

Payment of finance lease obligations

 

(170

)

 

(215

)

Net cash provided by (used in) financing activities

 

4,981,080

 

 

(2,050

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

5,065,861

 

 

(1,866

)

Cash, cash equivalents and restricted cash, beginning of year

 

6,143

 

 

8,009

 

Cash, cash equivalents and restricted cash, end of year

$

5,072,004

 

$

6,143

 

Cash paid during year for:

 

 

Interest

$

63

 

$

57

 

Income taxes

$

$

301

 
 

 QXO, INC. AND SUBSIDIARIES

RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA

(in thousands)

(Unaudited)

 
 

Three Months Ended December 31,

Year Ended December 31,

2024

 

2023

 

2024

2023

 

Net income (loss)

$

11,289

 

$

419

 

$

27,969

 

$

(1,070

)

Add (deduct):

 

 

 

 

 

Depreciation and amortization

 

271

 

 

262

 

 

1,122

 

 

1,001

 

Share-based compensation

 

20,528

 

 

 

 

34,513

 

 

41

 

Interest (income) expense

 

(61,374

)

 

14

 

 

(121,812

)

 

56

 

Provision (benefit) for income taxes

 

16,984

 

 

(11

)

 

22,843

 

 

(297

)

Transaction costs

 

4,647

 

 

 

 

12,765

 

 

2,986

 

Severance costs

 

 

 

 

 

2,768

 

 

 

Adjusted EBITDA

$

(7,655

)

$

684

 

$

(19,832

)

$

2,717

 

 

Media Contact:

Joe Checkler

[email protected]

203-609-9650

Investor Contact:

Mark Manduca

[email protected]

203-321-3889

KEYWORDS: United States North America Connecticut

INDUSTRY KEYWORDS: Commercial Building & Real Estate Software Construction & Property Building Systems Trucking Technology Logistics/Supply Chain Management Transport

MEDIA:

Logo
Logo

Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products


First three consumer products expected to launch in Q3 2025, providing near-term revenue growth

Jupiter, Florida, March 04, 2025 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, today announced a strategic partnership with Aquanova AG to jointly develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan.

“As we explore new ways to translate our scientific discoveries into tangible health solutions, we see an immense opportunity in the longevity and healthspan market,” said Christer Rosén, Chairman & CEO of Jupiter Neurosciences. “Aquanova has been an exceptional technology partner, and their expertise in formulation and execution will be instrumental in this venture. We believe that our pharmaceutical-driven approach and the strong clinical foundation behind JOTROL provide a unique advantage in delivering high-quality, effective products to consumers.”

Jupiter and Aquanova have collaborated for over eight years in the development of Jupiter’s lead product, JOTROL, a proprietary resveratrol-based formulation currently advancing toward a Phase IIa trial in Parkinson’s Disease. Based on the extensive preclinical and clinical data supporting JOTROL’s potential in central nervous system (CNS) disorders such as Alzheimer’s and Parkinson’s, the companies are now leveraging their combined expertise to expand into the rapidly growing longevity and healthspan market.

The jointly developed products will focus on the concept of “Beauty from Within,” emphasizing scientifically backed formulations designed to support longevity and overall health. The first three products are expected to launch in Q3 2025 through a Direct-to-Consumer (DTC) model, providing an immediate commercial pathway while Jupiter continues its clinical development efforts.

“We are incredibly proud of our partnership with Jupiter and look forward to the work they are doing to bring life-changing solutions for rare and difficult-to-treat diseases to market in the medicinal sphere and for superior supplement products targeting longevity and healthspan,” said Frank Behnam, CEO of Aquanova. “Resveratrol is a powerful ingredient but it suffers from bioavailability and absorption challenges. Our NovaSOLtechnology ensures that resveratrol safely reaches effective levels in the body, without GI-side effects, creating reliable health solutions in many indications.”

As part of this initiative, Jupiter plans to launch these products under a new wholly owned subsidiary, allowing existing shareholders to participate in the commercial success of the venture. This subsidiary is expected to generate revenue which will support Jupiter’s ongoing pharmaceutical trials.

“We frequently hear from individuals interested in accessing JOTROL immediately, particularly those with personal connections to neurodegenerative diseases,” Rosén added. “Like many, I have seen the devastating impact of Alzheimer’s and Parkinson’s firsthand. This initiative not only represents a strategic business expansion but also a meaningful step in addressing a growing consumer demand for science-backed solutions in aging and healthspan.”

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.

About JOTROL

Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.

Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL toward a Phase IIa trial in Parkinson’s Disease.

About Aquanova & NovaSOL

®

Technology

Aquanova NA Corp. is the U.S. daughter company of Aquanova AG, headquartered in Germany, a leading phyto-technology manufacturer dedicated to enhancing the bioavailability of natural compounds. Founded in 1995, Aquanova AG offers scientifically proven health ingredients to customers worldwide. Utilizing its patented NovaSOL® technology, the company delivers micellized ingredients with superior efficacy and speed of absorption. www.aquanovacorp.com/ www.aquanova.de

FORWARD-LOOKING STATEMENTS

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the Company’s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.

Contact:

Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
[email protected]



Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences:

Leerink Partners 2025 Global Healthcare Conference

Tuesday, March 11, 2025

Jefferies Biotech on the Beach Summit

Wednesday, March 12, 2025

Barclays 27

th

Annual Global Healthcare Conference

Thursday, March 13, 2025

About Collegium Pharmaceutical, Inc.

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Investor Contacts:

Ian Karp
Head of Investor Relations
[email protected]

Danielle Jesse
Director, Investor Relations
[email protected]

Media Contact:

Cheryl Wheeler
Head of Corporate Communications
[email protected]



FICO Teams Up with Pro Volleyball Federation to Champion Financial Literacy for Volleyball Athletes and Fans

FICO Teams Up with Pro Volleyball Federation to Champion Financial Literacy for Volleyball Athletes and Fans

FICO’s sponsorship focuses on raising awareness of financial literacy and credit education through volleyball athletes, engaging fellow athletes and fans to make informed financial decisions

BOZEMAN, Mont.–(BUSINESS WIRE)–
Global analytics software leader, FICO has announced its sponsorship of Pro Volleyball Federation (PVF) for the 2025 season. Through this partnership, FICO will help raise awareness of financial literacy and credit education by engaging PVF athletes to share valuable insights including free access to myFICO, where they can check and monitor their FICO® Score. PVF athletes will also engage with fellow players and fans on social media channels to share experiences with and ways to access this valuable credit education content throughout the season to empower them to make better informed financial decisions and build foundations for a stronger financial future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250304026219/en/

Pro Volleyball Federation (Graphic: FICO)

Pro Volleyball Federation (Graphic: FICO)

PVF is the premier professional volleyball league in North America, offering top athletes the opportunity to compete at the highest level. Since its launch in 2024, PVF has experienced rapid growth, with record-breaking attendance, drawing more than 575,000 fans, millions of online viewers, and national media coverage, all reflecting the rising popularity of women’s volleyball across the U.S.

“The energy surrounding professional women’s volleyball has never been greater, and welcoming an industry-leading organization like FICO underscores the growing impact of our league,” said Jen Spicher, CEO at Pro Volleyball Federation. “Financial literacy and credit education play an important role in the lives of athletes and fans alike, and this collaboration adds another layer of support as they navigate their financial futures.”

FICO has long been committed to helping drive financial empowerment through credit education. The company works with students, adults, and community organizations to improve financial literacy in communities across the U.S. Research shows that individuals who track their FICO® Scores are more likely to have higher scores and fewer late payments. Knowing and tracking your FICO Score can improve financial decision-making.

A recent Harris Poll survey commissioned by FICO found that 3 in 5 Americans (60%), including 50% of Gen Z (ages 18-27), believe personal finance is one of the most useful subjects in adulthood that can be taught in high school. Additionally, 25% of Gen Z feel that a lack of personal finance skills has prevented them from achieving financial goals. Furthermore, many Gen Z (43%) also believe that banks and financial institutions should be most responsible for educating people on how to manage their finances, such as using credit responsibly, managing debt, and saving for retirement. These insights reveal a strong demand for credit education, especially among younger generations looking to manage their financial futures.

“Financial health is just as crucial as preparation and strategy in sports,” said Jenelle Dito, Vice President of Consumer Empowerment Programs and Partnerships at FICO. “At FICO, we’re excited to raise awareness about financial literacy and credit education, empowering volleyball fans and athletes to make more confident and informed financial decisions.”

The FICO® Score is used by 90% of top U.S. lenders. Lenders use FICO Scores to extend credit for personal loans, mortgages, auto loans, credit cards, and more, which is why it is so important for people to know their FICO Score and what is impacting it.

FICO offers resources to help people kick-start their financial literacy and credit education journey. For example, myFICO lets consumers check and monitor their FICO® Score for free. Plus, FICO continually updates the website and app with credit education materials and tools designed to help people understand their credit.

To check your FICO® Score for free, go to: https://www.myfico.com/free.

To learn more information about FICO’s credit education programs, FICO’s Score A Better Future™ and FICO’s Score A Better Future™ Fundamentals program, visit: https://www.fico.com/sabf/.

ABOUT PRO VOLLEYBALL FEDERATION

Pro Volleyball Federation is the leading professional volleyball league in the United States. PVF sets the standard for the sport, offering the largest number of franchises, unmatched attendance, extensive broadcast coverage and substantial championship prize money. It combines top-tier talent, including NCAA stars and international athletes, with cutting-edge production and technology to provide fans with an unmatched viewing experience. As a vital link between collegiate volleyball and the professional stage, PVF is dedicated to shaping the future of the sport and increasing visibility for its athletes. For more information, visit ProVolleyball.com.

About FICO

FICO (NYSE: FICO) powers decisions that help people and businesses around the world prosper. Founded in 1956, the company is a pioneer in the use of predictive analytics and data science to improve operational decisions. FICO holds more than 200 US and foreign patents on technologies that increase profitability, customer satisfaction and growth for businesses in financial services, insurance, telecommunications, health care, retail and many other industries. Using FICO solutions, businesses in more than 80 countries do everything from protecting four billion payment cards from fraud, to improving financial inclusion, to increasing supply chain resiliency. The FICO® Score, used by 90% of top US lenders, is the standard measure of consumer credit risk in the US and has been made available in over 40 other countries, improving risk management, credit access and transparency.

Learn more at https://www.fico.com/en.

Join the conversation at https://x.com/FICO_corp & https://www.fico.com/blogs/.

For FICO news and media resources, visit https://www.fico.com/en/newsroom.

FICO and Score A Better Future are trademarks or registered trademarks of Fair Isaac Corporation in the U.S. and other countries.

FICO Media Contact

Julie Huang

[email protected]

Pro Volleyball Federation Media Contact

Rob Carolla

[email protected]

KEYWORDS: United States North America Montana

INDUSTRY KEYWORDS: Banking Technology Men Professional Services Volleyball Social Media Sports Consumer Data Analytics Other Education Communications Software Education Women General Sports Finance Consulting

MEDIA:

Photo
Photo
Pro Volleyball Federation (Graphic: FICO)
Logo
Logo

Westwood Announces Monthly Income Distributions for Westwood Salient Enhanced Midstream Income ETF (MDST) and Westwood Salient Enhanced Energy Income ETF (WEEI)

DALLAS, March 04, 2025 (GLOBE NEWSWIRE) — Westwood Holdings Group (WHG), a publicly-traded investment management boutique and wealth management firm, today announced monthly income distributions for Westwood Salient Enhanced Midstream Income ETF (NYSE: MDST) and Westwood Salient Enhanced Energy Income ETF (NASDAQ: WEEI) as shown in the table below. This pair of Westwood Exchange- Traded Funds (ETFs) deliver income from both dividends and options premiums to help provide monthly income distributions for investors. Most recently, both strategies are providing double-digit income to investors.

ETF Ticker ETF Distribution per Share Annualized DistributionRate

1

(NYSE:
MDST)
Westwood Salient Enhanced Midstream Income ETF 0.225 10.0%

(NASDAQ:
WEEI)
Westwood Salient Enhanced Energy Income ETF 0.225 12.3%


Both MDST and WEEI are actively managed funds, designed to provide advisors and investors with a robust solution for generating high distributable monthly income, combining dividend yield (distributions paid from the Fund’s net investment income) and options premiums from covered calls, while also offering the potential for equity appreciation within the energy sector.

Launched April 8, 2024, MDST seeks to deliver current income and capital appreciation by investing in midstream energy companies, defined as companies and master limited partnerships (MLPs) that gather, transport, store and distribute crude oil, natural gas and other energy products. The fund combines dividend yield and options premiums from covered calls to target monthly income distributions. MDST currently has $81 million in net assets, as of February 27, 2025.

WEEI, which launched April 30, 2024, offers broad exposure to energy companies, including upstream, downstream, oil service and integrated companies that operate in all phases of oil exploration, production, service and distribution. Like MDST, WEEI combines dividend yield and options premiums from covered calls to target monthly income distributions. WEEI currently has $16 million in net assets as of February 27, 2025.

Standardized Performance as of 12/31/24 QTD Since
Inception
MDST Inception: April 8, 2024
Expense ratio: 0.80%
MDST Fund NAV (%) 7.52% 16.31%
MDST Market Price (%) 7.89% 16.92%
WEEI Inception: April 30, 2024
Expense ratio: 0.85%
WEEI Fund NAV (%) -1.77% -4.22%
WEEI Market Price (%) -1.78% -4.19%
Subsidized/Unsubsidized 30-Day Yield
MDST 4.05%/4.05%        WEEI 2.45%/2.45%



The performance data quoted represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor’s shares, when redeemed, may be worth more or less than their original cost. For performance information current to the most recent month-end, please call toll-free (877) 386- 3944.

NAV Return represents the closing price of underlying securities. Market Return is calculated using the price which investors buy and sell ETF shares in the market. The market returns in the table are based upon the midpoint of the bid/ask spread at 4:00 pm EST, and do not represent the returns you would have received if you traded shares at other times.

1The Annualized Distribution Rate shown is as of February 27, 2025. The Annualized Distribution Rate is the rate an investor would receive if the most recent distribution, which includes option premium income, remained the same going forward. The Annualized Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV. The Distribution Rate represents a single distribution from the ETF and does not represent its total return. The current months distribution is 100% return of capital (ROC) for MDST and 23.15% ROC for WEEI. Distributions may also include a combination of ordinary dividends, capital gain, and return of investor capital, which may decrease an ETF’s NAV and trading price over time. As a result, an investor may suffer significant losses to their investment. These Distribution Rates may be caused by unusually favorable market conditions and may not be sustainable. Such conditions may not continue to exist and there should be no expectation that this performance may be repeated in the future.

More information on Westwood’s ETF offerings is available at westwoodetfs.com.

ABOUT WESTWOOD HOLDINGS GROUP, INC.

Westwood Holdings Group, Inc. is a focused investment management boutique and wealth management firm.

Founded in 1983, Westwood offers a broad array of investment solutions to institutional investors, private wealth clients and financial intermediaries. The firm specializes in several distinct investment capabilities: U.S. Value Equity, Multi-Asset, Energy & Real Assets, Income Alternatives, Tactical Absolute Return and Managed Investment Solutions, which are available through separate accounts, the Westwood Funds® family of mutual funds, exchange-traded funds (ETFs) and other pooled vehicles. Westwood benefits from significant, broad-based employee ownership and trades on the New York Stock Exchange under the symbol “WHG.” Based in Dallas, Westwood also maintains offices in Chicago, Houston and San Francisco.

For more information on Westwood, please visit westwoodgroup.com.

Westwood ETFs are distributed by Northern Lights Distributors, LLC (Member FINRA). Northern Lights Distributors and Westwood ETFs (or Westwood Holdings Group, Inc.) are separate and unaffiliated.

To determine if these Funds are an appropriate investment for you, carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and other information can be found in the Fund prospectus’, which may be obtained by calling 800.944.0755. Please read the prospectus carefully before investing.

The Funds are newly formed and have limited operating history.

The Fund’s investments are concentrated in the energy infrastructure industry with an emphasis on securities issued by MLPs, which may increase price fluctuation. The value of commodity-linked investments such as the MLPs and energy infrastructure companies (including midstream MLPs and energy infrastructure companies) in which the Fund invests are subject to risks specific to the industry they serve, such as fluctuations in commodity prices, reduced volumes of available natural gas or other energy commodities, slowdowns in new construction and acquisitions, a sustained reduced demand for crude oil, natural gas and refined petroleum products, depletion of the natural gas reserves or other commodities, changes in the macroeconomic or regulatory environment, environmental hazards, rising interest rates and threats of attack by terrorists on energy assets, each of which could affect the Fund’s profitability. Covered Call Strategy Risk: This risk arises when an investor holds a long position in a stock and simultaneously sells a call option against it. While this strategy can generate income, it limits potential upside gains if the stock price rises significantly above the strike price of the option. Options Risk/Flex Options Risk: This refers to the inherent risks associated with trading options, such as the risk of losing the entire premium paid for an option if it expires out-of-the-money. Flex options risk is a specific type of options risk that arises from the flexibility of flex options, which can be adjusted or exercised under certain conditions.

The SEC 30-Day Yield represents net investment income earned by the Fund over a 30-day period, expressed as an annual percentage rate based on the Fund’s share price at the end of the 30-day period. 30-day SEC yield is a standardized calculation adopted by the SEC based on a 30-day period that helps investors compare funds using a consistent method of calculating yield. The subsidized yield includes the effect of any fee waivers or expense reimbursements, while the unsubsidized yield excludes these cost reductions, showing what the yield would be if the fund had to cover all expenses from its own income. Options Premiums is the price paid to purchase an option contract. Covered Call Option is a financial contract that gives the holder the right, but not the obligation, to buy a specific asset at a predetermined price (strike price) within a specified time period. Dividend Yield is a dividend expressed as a percentage of a current share price.

MLPs are subject to significant regulation and may be adversely affected by changes in the regulatory environment including the risk that an MLP could lose its tax status as a partnership. If an MLP were to be obligated to pay federal income tax on its income at the corporate tax rate, the amount of cash available for distribution would be reduced and such distributions received by the Fund would be taxed under federal income tax laws applicable to corporate dividends received (as dividend income, return of capital or capital gain). Investing in MLPs involves additional risks as compared to the risks of investing in common stock, including risks related to cash flow, dilution and voting rights. Such companies may trade less frequently than larger companies due to their smaller capitalizations, which may result in erratic price movement or difficulty in buying or selling. Additional management fees and other expenses are associated with investing in MLP funds. The tax benefits received by an investor investing in the Fund differs from that of a direct investment in an MLP by an investor. This document does not constitute an offering of any security, product, service or fund, including the Fund, for which an offer can be made only by the Fund’s prospectus. No fund is a complete investment program and you may lose money investing in a fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.

MediaContact:

Tyler Bradford
HewesCommunications
212.207.9454



[email protected]